Skip to main content

Eligard (leuprorelin acetate) | For UK Healthcare Professionals

This promotional website has been developed and funded by Recordati Pharmaceuticals Ltd and is only intended for healthcare professionals based in the UK.
Prescribing Information (PI) and Adverse Event (AE) Reporting Information can be accessed via the link found at the bottom of this page.
For your patients with advanced
prostate cancer -

It's about time.

As few as two injections per year (with 6‑monthly dosing option).1

Sustained testosterone suppression.1

Over 20 years of experience.*2

ELIGARD (leuprorelin acetate) is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.1

*With over 4 million patient-years’ real-world experience

and efficacy and safety data from over 17 published clinical trials, you can be assured that ELIGARDâ„¢ will reliably suppress testosterone for as long as your patients need1-7